Navigation Links
Sanofi-aventis Delivers 2008 Results Above Guidance
Date:2/11/2009

with double-digit growth in all three regions: 15.9% in the United States, 10.8% in Europe, and 13.8% in the "Other Countries" region.

(3) Excluding net sales of Ambien IR(R) in the United States in Q1 2007 and Q1 2008, and of Eloxatin(R) in Europe in 2007 and 2008

Fourth-quarter net sales of the hypnotics Ambien CR(R) and Ambien IR(R) in the United States were $170 million and $24 million respectively. Over the full year, net sales of Ambien CR(R) totaled $681 million, and Ambien IR(R) posted net sales of $125 million. In Japan, Myslee(R), the leading hypnotic on the market, again performed well: net sales (consolidated by sanofi-aventis since January 1, 2008) increased by 17.8% (to EUR 49 million) in the fourth quarter and by 14.9% (to EUR 142 million) over the full year.

In the United States, net sales of Eloxatin(R), the leading cytotoxic agent in the colorectal cancer market as an adjuvant and in the metastatic phase, rose by 6.9% to EUR 265 million in the fourth quarter and by 6.2% to EUR 948 million over 2008 as a whole, driven by the adjuvant indication. In the "Other Countries" region, the product reported robust growth of 13.4% to EUR 186 million.

Net sales of Acomplia(R), which was withdrawn from the market in the fourth quarter, totaled EUR 72 million in 2008.

Worldwide presence(1) of Plavix(R) / Iscover(R)

    EUR million                         Change on a          Change on a
                                         comparable           comparable
                                Q4 2008     basis   FY 2008      basis
    Europe                        457        +1.8%   1,833        +3.2%
    United States                 978       +11.6%   3,351       +21.1%
    Other Countries               270       +19.5%     959       +22.0%
    TOTAL                       1,
'/>"/>
SOURCE  sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 

Related medicine news :

1. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
3. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
4. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
5. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
6. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
7. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
8. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
9. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
10. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
11. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... 2013 HealthEconomics.Com , the global ... to unveil a new and exciting service: HE-Xpo: a ... powerful array of real-time communication tools to expand their ... abroad. , HE-Xpo is powered by OnStream Media’s ... and feel of being at a physical trade show, ...
(Date:5/19/2013)... 2013 The Da Vinci robot lawyers ... in the nation’s first trial involving a Da Vinci ... State Superior Court, was filed by the widow of ... complications in a robot-assisted prostate removal, according to a ... robotic surgery lawsuit alleges those complication’s hastened his ...
(Date:5/18/2013)... 18, 2013 Daily Gossip issued a press ... review on their page. John Colston, Daily Gossip’s spokesperson, told ... Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan . ... carbs are healthy at a time when nutritionists and fat ... caloric products. , The diet is based on the ...
(Date:5/18/2013)... American Gastroenterological Association (AGA) Research Foundation is pleased ... honorees are outstanding young gastroenterologists working toward independent ... with this award, their research time will be ... future of our field. AGA is committed to ... for promising research developments and new therapies," said ...
Breaking Medicine News(10 mins):Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2
... , ... ... ... ...
... ... role , ... February 25, 2010 -- LocumTenens.com has named Lisa Kaeck as Executive Vice ... of service at LocumTenens.com., , , , ,A founding partner of LocumTenens.com, Kaeck has more ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... Outlawing Health Insurance Monopolies Would Be Good for Doctors, Patients , ...
... cancer patients receiving induction chemotherapy followed by radiation to ... disability and almost half experienced no eating or swallowing ... presented at the Multidisciplinary Head and Neck Cancer Symposium, ... removal with permanent tracheotomy is the current standard treatment ...
Cached Medicine News:Health News:Good Parenting Triumphs Over Prenatal Stress 2Health News:Good Parenting Triumphs Over Prenatal Stress 3Health News:Good Parenting Triumphs Over Prenatal Stress 4Health News:Good Parenting Triumphs Over Prenatal Stress 5Health News:Good Parenting Triumphs Over Prenatal Stress 6Health News:LocumTenens.com Names Lisa Kaeck Executive Vice President 2Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 2Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 3Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 4Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 2Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 3Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 4Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 5Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 6Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 7Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 2Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 3
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... BOZEN, SUD-TIROL, Italy , July 27, 2010 ... assets from, Italy -based MEDarchiver S.r.l. and Biomedical Technology Consulting S.r.l.,merging ... market, and conducting a re-organization of its,Executive Management, expecting to close ... , , ...
... Sysmex America, Inc., a leading medical diagnostic ... to debut its expanded cell image analysis portfolio during ... Conference and Clinical Lab Expo July 25 - ... DM1200 and DM96 systems for the mid-size to larger ...
Cached Medicine Technology:Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 2Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 3Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 4Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 2Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 3
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: